Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2016

Open Access 01-12-2016 | Research article

Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis

Authors: Marcin Okrój, Martin Johansson, Tore Saxne, Anna M. Blom, Roger Hesselstrand

Published in: Arthritis Research & Therapy | Issue 1/2016

Login to get access

Abstract

Background

The complement system has been implicated in pathogenesis of systemic sclerosis (SSc). The goal of the present study was to evaluate improved complement biomarkers in SSc.

Methods

The presence of C4d, reflecting activation of the classical/lectin pathways, C3bBbP corresponding to activation of the alternative pathway, and soluble terminal complement complexes (all complement pathways), was measured in plasma samples by enzyme-linked immunosorbent assay and correlated to clinical parameters. The study included 81 patients with limited cutaneous SSc and 41 with diffuse cutaneous SSc, as well as 47 matched healthy controls and 81 patients with rheumatoid arthritis, 22 with psoriatic arthritis and 20 with ankylosing spondylitis. Skin and kidney biopsies of selected patients were stained to detect deposited C3b as a marker of local complement activation.

Results

Biomarkers of activation of all complement pathways were increased in SSc compared with healthy controls and were similar to those in other rheumatic diseases. When patients with SSc were divided into subgroups, a distinct pattern of complement markers was observed in individuals with scleroderma renal crisis (SRC). By functional assay, we confirmed a significant decrease in complement haemolytic activity in SRC vs. non-SRC patients, indicating complement consumption. Further, we detected glomerular deposits of C3b in some patients with SRC.

Conclusions

The data indicate that complement activation is an important feature of SRC.
Literature
1.
go back to reference Balbir-Gurman A, Braun-Moscovici Y. Scleroderma – new aspects in pathogenesis and treatment. Best Pract Res Clin Rheumatol. 2012;26:13–24.CrossRefPubMed Balbir-Gurman A, Braun-Moscovici Y. Scleroderma – new aspects in pathogenesis and treatment. Best Pract Res Clin Rheumatol. 2012;26:13–24.CrossRefPubMed
3.
go back to reference LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.PubMed LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.PubMed
4.
go back to reference Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 1995;3:39–50.CrossRefPubMed Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 1995;3:39–50.CrossRefPubMed
5.
go back to reference Streicher K, Morehouse CA, Groves CJ, Rajan B, Pilataxi F, Lehmann KP, et al. The plasma cell signature in autoimmune disease. Arthritis Rheumatol. 2014;66:173–84.CrossRefPubMed Streicher K, Morehouse CA, Groves CJ, Rajan B, Pilataxi F, Lehmann KP, et al. The plasma cell signature in autoimmune disease. Arthritis Rheumatol. 2014;66:173–84.CrossRefPubMed
6.
go back to reference Chizzolini C, Raschi E, Rezzonico R, Testoni C, Mallone R, Gabrielli A, et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum. 2002;46:1602–13.CrossRefPubMed Chizzolini C, Raschi E, Rezzonico R, Testoni C, Mallone R, Gabrielli A, et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum. 2002;46:1602–13.CrossRefPubMed
7.
go back to reference Tedder TF, Poe JC, Fujimoto M, Haas KM, Sato S. The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Curr Dir Autoimmun. 2005;8:55–90.CrossRefPubMed Tedder TF, Poe JC, Fujimoto M, Haas KM, Sato S. The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Curr Dir Autoimmun. 2005;8:55–90.CrossRefPubMed
8.
go back to reference Swierczynska Z, Rdultowska H, Blaszczyk M, Jablonska S, Luft S. Circulating immune complexes in systemic scleroderma. Immunol Commun. 1984;13:433–8.CrossRefPubMed Swierczynska Z, Rdultowska H, Blaszczyk M, Jablonska S, Luft S. Circulating immune complexes in systemic scleroderma. Immunol Commun. 1984;13:433–8.CrossRefPubMed
9.
go back to reference Siminovitch K, Klein M, Pruzanski W, Wilkinson S, Lee P, Yoon SJ, et al. Circulating immune complexes in patients with progressive systemic sclerosis. Arthritis Rheum. 1982;25:1174–9.CrossRefPubMed Siminovitch K, Klein M, Pruzanski W, Wilkinson S, Lee P, Yoon SJ, et al. Circulating immune complexes in patients with progressive systemic sclerosis. Arthritis Rheum. 1982;25:1174–9.CrossRefPubMed
10.
go back to reference Senaldi G, Lupoli S, Vergani D, Black CM. Activation of the complement system in systemic sclerosis: relationship to clinical severity. Arthritis Rheum. 1989;32:1262–7.CrossRefPubMed Senaldi G, Lupoli S, Vergani D, Black CM. Activation of the complement system in systemic sclerosis: relationship to clinical severity. Arthritis Rheum. 1989;32:1262–7.CrossRefPubMed
11.
go back to reference Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34:J276–86.CrossRefPubMed Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34:J276–86.CrossRefPubMed
12.
go back to reference Blom AM, Osterborg A, Mollnes TE, Okroj M. Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Mol Immunol. 2015;66:164–70.CrossRefPubMed Blom AM, Osterborg A, Mollnes TE, Okroj M. Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Mol Immunol. 2015;66:164–70.CrossRefPubMed
13.
go back to reference Okroj M, Heinegard D, Holmdahl R, Blom AM. Rheumatoid arthritis and the complement system. Ann Med. 2007;39:517–30.CrossRefPubMed Okroj M, Heinegard D, Holmdahl R, Blom AM. Rheumatoid arthritis and the complement system. Ann Med. 2007;39:517–30.CrossRefPubMed
14.
go back to reference Chimenti MS, Perricone C, Graceffa D, Di Muzio G, Ballanti E, Guarino MD, et al. Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol. 2012;30:23–30.PubMed Chimenti MS, Perricone C, Graceffa D, Di Muzio G, Ballanti E, Guarino MD, et al. Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol. 2012;30:23–30.PubMed
15.
go back to reference McGuigan LE, Geczy AF, Edmonds JP. The immunopathology of ankylosing spondylitis—a review. Semin Arthritis Rheum. 1985;15:81–105.CrossRefPubMed McGuigan LE, Geczy AF, Edmonds JP. The immunopathology of ankylosing spondylitis—a review. Semin Arthritis Rheum. 1985;15:81–105.CrossRefPubMed
16.
go back to reference Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581–90. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581–90.
17.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.CrossRefPubMed
18.
go back to reference Otteby KE, Holmquist E, Saxne T, Heinegard D, Hesselstrand R, Blom AM. Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis. Arthritis Res Ther. 2013;15:R215.CrossRefPubMedPubMedCentral Otteby KE, Holmquist E, Saxne T, Heinegard D, Hesselstrand R, Blom AM. Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis. Arthritis Res Ther. 2013;15:R215.CrossRefPubMedPubMedCentral
19.
go back to reference Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281–5.PubMed Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281–5.PubMed
20.
go back to reference Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol. 2013;56:232–9.CrossRefPubMed Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol. 2013;56:232–9.CrossRefPubMed
21.
go back to reference Okroj M, Holmquist E, Sjolander J, Corrales L, Saxne T, Wisniewski HG, et al. Heavy chains of inter alpha inhibitor (IαI) inhibit the human complement system at early stages of the cascade. J Biol Chem. 2012;287:20100–10.CrossRefPubMedPubMedCentral Okroj M, Holmquist E, Sjolander J, Corrales L, Saxne T, Wisniewski HG, et al. Heavy chains of inter alpha inhibitor (IαI) inhibit the human complement system at early stages of the cascade. J Biol Chem. 2012;287:20100–10.CrossRefPubMedPubMedCentral
22.
go back to reference Hesselstrand R, Kassner A, Heinegard D, Saxne T. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker. Ann Rheum Dis. 2008;67:1242–8.CrossRefPubMed Hesselstrand R, Kassner A, Heinegard D, Saxne T. COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker. Ann Rheum Dis. 2008;67:1242–8.CrossRefPubMed
23.
go back to reference Happonen KE, Saxne T, Aspberg A, Mörgelin M, Heinegård D, Blom AM. Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum. 2010;62:3574–83.CrossRefPubMedPubMedCentral Happonen KE, Saxne T, Aspberg A, Mörgelin M, Heinegård D, Blom AM. Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum. 2010;62:3574–83.CrossRefPubMedPubMedCentral
24.
go back to reference Batal I, Domsic RT, Shafer A, Medsger Jr TA, Kiss LP, Randhawa P, et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol. 2009;40:332–40.CrossRefPubMed Batal I, Domsic RT, Shafer A, Medsger Jr TA, Kiss LP, Randhawa P, et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol. 2009;40:332–40.CrossRefPubMed
25.
go back to reference Denton CP, Lapadula G, Mouthon L, Müller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology (Oxford). 2009;48 Suppl 3:iii32–5. Denton CP, Lapadula G, Mouthon L, Müller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology (Oxford). 2009;48 Suppl 3:iii32–5.
26.
go back to reference Steen VD, Costantino JP, Shapiro AP, Medsger Jr TA. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990;113:352–7.CrossRefPubMed Steen VD, Costantino JP, Shapiro AP, Medsger Jr TA. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990;113:352–7.CrossRefPubMed
27.
go back to reference Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007;100:485–94.CrossRefPubMed Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007;100:485–94.CrossRefPubMed
28.
go back to reference Hesselstrand R, Scheja A, Wuttge DM. Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand J Rheumatol. 2012;41:39–43.CrossRefPubMed Hesselstrand R, Scheja A, Wuttge DM. Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand J Rheumatol. 2012;41:39–43.CrossRefPubMed
29.
go back to reference Sturfelt G, Truedsson L. Complement in the immunopathogenesis of rheumatic disease. Nat Rev Rheumatol. 2012;8:458–68.CrossRefPubMed Sturfelt G, Truedsson L. Complement in the immunopathogenesis of rheumatic disease. Nat Rev Rheumatol. 2012;8:458–68.CrossRefPubMed
30.
go back to reference Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol. 1998;37:15–20.CrossRefPubMed Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol. 1998;37:15–20.CrossRefPubMed
Metadata
Title
Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis
Authors
Marcin Okrój
Martin Johansson
Tore Saxne
Anna M. Blom
Roger Hesselstrand
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2016
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-016-1168-x

Other articles of this Issue 1/2016

Arthritis Research & Therapy 1/2016 Go to the issue